A Phase I/II randomized trial of H56:IC31 vaccination and adjunctive cyclooxygenase-2-inhibitor treatment in tuberculosis patients
Modulating the host immune response during tuberculosis is an emerging and critical advance in the therapeutic approach. Here the authors present data from a first-in-human phase I/II randomised trial on the safety and immunogenicity of adjuvant therapy of the H56:IC31 vaccine and cyclooxygenase-2 i...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/6152a3f5e03b4794a0706ed5b7ac2925 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:6152a3f5e03b4794a0706ed5b7ac2925 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:6152a3f5e03b4794a0706ed5b7ac29252021-11-28T12:33:09ZA Phase I/II randomized trial of H56:IC31 vaccination and adjunctive cyclooxygenase-2-inhibitor treatment in tuberculosis patients10.1038/s41467-021-27029-62041-1723https://doaj.org/article/6152a3f5e03b4794a0706ed5b7ac29252021-11-01T00:00:00Zhttps://doi.org/10.1038/s41467-021-27029-6https://doaj.org/toc/2041-1723Modulating the host immune response during tuberculosis is an emerging and critical advance in the therapeutic approach. Here the authors present data from a first-in-human phase I/II randomised trial on the safety and immunogenicity of adjuvant therapy of the H56:IC31 vaccine and cyclooxygenase-2 inhibitors in patients with tuberculosis.Synne JenumKristian TonbyCorina S. RueeggMorten RühwaldMax P. KristiansenPeter BangInge Christoffer OlsenKjersti SellægKjerstin RøstadTehmina MustafaKjetil TaskénDag KvaleRasmus MortensenAnne Ma Dyrhol-RiiseNature PortfolioarticleScienceQENNature Communications, Vol 12, Iss 1, Pp 1-13 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Science Q |
| spellingShingle |
Science Q Synne Jenum Kristian Tonby Corina S. Rueegg Morten Rühwald Max P. Kristiansen Peter Bang Inge Christoffer Olsen Kjersti Sellæg Kjerstin Røstad Tehmina Mustafa Kjetil Taskén Dag Kvale Rasmus Mortensen Anne Ma Dyrhol-Riise A Phase I/II randomized trial of H56:IC31 vaccination and adjunctive cyclooxygenase-2-inhibitor treatment in tuberculosis patients |
| description |
Modulating the host immune response during tuberculosis is an emerging and critical advance in the therapeutic approach. Here the authors present data from a first-in-human phase I/II randomised trial on the safety and immunogenicity of adjuvant therapy of the H56:IC31 vaccine and cyclooxygenase-2 inhibitors in patients with tuberculosis. |
| format |
article |
| author |
Synne Jenum Kristian Tonby Corina S. Rueegg Morten Rühwald Max P. Kristiansen Peter Bang Inge Christoffer Olsen Kjersti Sellæg Kjerstin Røstad Tehmina Mustafa Kjetil Taskén Dag Kvale Rasmus Mortensen Anne Ma Dyrhol-Riise |
| author_facet |
Synne Jenum Kristian Tonby Corina S. Rueegg Morten Rühwald Max P. Kristiansen Peter Bang Inge Christoffer Olsen Kjersti Sellæg Kjerstin Røstad Tehmina Mustafa Kjetil Taskén Dag Kvale Rasmus Mortensen Anne Ma Dyrhol-Riise |
| author_sort |
Synne Jenum |
| title |
A Phase I/II randomized trial of H56:IC31 vaccination and adjunctive cyclooxygenase-2-inhibitor treatment in tuberculosis patients |
| title_short |
A Phase I/II randomized trial of H56:IC31 vaccination and adjunctive cyclooxygenase-2-inhibitor treatment in tuberculosis patients |
| title_full |
A Phase I/II randomized trial of H56:IC31 vaccination and adjunctive cyclooxygenase-2-inhibitor treatment in tuberculosis patients |
| title_fullStr |
A Phase I/II randomized trial of H56:IC31 vaccination and adjunctive cyclooxygenase-2-inhibitor treatment in tuberculosis patients |
| title_full_unstemmed |
A Phase I/II randomized trial of H56:IC31 vaccination and adjunctive cyclooxygenase-2-inhibitor treatment in tuberculosis patients |
| title_sort |
phase i/ii randomized trial of h56:ic31 vaccination and adjunctive cyclooxygenase-2-inhibitor treatment in tuberculosis patients |
| publisher |
Nature Portfolio |
| publishDate |
2021 |
| url |
https://doaj.org/article/6152a3f5e03b4794a0706ed5b7ac2925 |
| work_keys_str_mv |
AT synnejenum aphaseiiirandomizedtrialofh56ic31vaccinationandadjunctivecyclooxygenase2inhibitortreatmentintuberculosispatients AT kristiantonby aphaseiiirandomizedtrialofh56ic31vaccinationandadjunctivecyclooxygenase2inhibitortreatmentintuberculosispatients AT corinasrueegg aphaseiiirandomizedtrialofh56ic31vaccinationandadjunctivecyclooxygenase2inhibitortreatmentintuberculosispatients AT mortenruhwald aphaseiiirandomizedtrialofh56ic31vaccinationandadjunctivecyclooxygenase2inhibitortreatmentintuberculosispatients AT maxpkristiansen aphaseiiirandomizedtrialofh56ic31vaccinationandadjunctivecyclooxygenase2inhibitortreatmentintuberculosispatients AT peterbang aphaseiiirandomizedtrialofh56ic31vaccinationandadjunctivecyclooxygenase2inhibitortreatmentintuberculosispatients AT ingechristofferolsen aphaseiiirandomizedtrialofh56ic31vaccinationandadjunctivecyclooxygenase2inhibitortreatmentintuberculosispatients AT kjerstisellæg aphaseiiirandomizedtrialofh56ic31vaccinationandadjunctivecyclooxygenase2inhibitortreatmentintuberculosispatients AT kjerstinrøstad aphaseiiirandomizedtrialofh56ic31vaccinationandadjunctivecyclooxygenase2inhibitortreatmentintuberculosispatients AT tehminamustafa aphaseiiirandomizedtrialofh56ic31vaccinationandadjunctivecyclooxygenase2inhibitortreatmentintuberculosispatients AT kjetiltasken aphaseiiirandomizedtrialofh56ic31vaccinationandadjunctivecyclooxygenase2inhibitortreatmentintuberculosispatients AT dagkvale aphaseiiirandomizedtrialofh56ic31vaccinationandadjunctivecyclooxygenase2inhibitortreatmentintuberculosispatients AT rasmusmortensen aphaseiiirandomizedtrialofh56ic31vaccinationandadjunctivecyclooxygenase2inhibitortreatmentintuberculosispatients AT annemadyrholriise aphaseiiirandomizedtrialofh56ic31vaccinationandadjunctivecyclooxygenase2inhibitortreatmentintuberculosispatients AT synnejenum phaseiiirandomizedtrialofh56ic31vaccinationandadjunctivecyclooxygenase2inhibitortreatmentintuberculosispatients AT kristiantonby phaseiiirandomizedtrialofh56ic31vaccinationandadjunctivecyclooxygenase2inhibitortreatmentintuberculosispatients AT corinasrueegg phaseiiirandomizedtrialofh56ic31vaccinationandadjunctivecyclooxygenase2inhibitortreatmentintuberculosispatients AT mortenruhwald phaseiiirandomizedtrialofh56ic31vaccinationandadjunctivecyclooxygenase2inhibitortreatmentintuberculosispatients AT maxpkristiansen phaseiiirandomizedtrialofh56ic31vaccinationandadjunctivecyclooxygenase2inhibitortreatmentintuberculosispatients AT peterbang phaseiiirandomizedtrialofh56ic31vaccinationandadjunctivecyclooxygenase2inhibitortreatmentintuberculosispatients AT ingechristofferolsen phaseiiirandomizedtrialofh56ic31vaccinationandadjunctivecyclooxygenase2inhibitortreatmentintuberculosispatients AT kjerstisellæg phaseiiirandomizedtrialofh56ic31vaccinationandadjunctivecyclooxygenase2inhibitortreatmentintuberculosispatients AT kjerstinrøstad phaseiiirandomizedtrialofh56ic31vaccinationandadjunctivecyclooxygenase2inhibitortreatmentintuberculosispatients AT tehminamustafa phaseiiirandomizedtrialofh56ic31vaccinationandadjunctivecyclooxygenase2inhibitortreatmentintuberculosispatients AT kjetiltasken phaseiiirandomizedtrialofh56ic31vaccinationandadjunctivecyclooxygenase2inhibitortreatmentintuberculosispatients AT dagkvale phaseiiirandomizedtrialofh56ic31vaccinationandadjunctivecyclooxygenase2inhibitortreatmentintuberculosispatients AT rasmusmortensen phaseiiirandomizedtrialofh56ic31vaccinationandadjunctivecyclooxygenase2inhibitortreatmentintuberculosispatients AT annemadyrholriise phaseiiirandomizedtrialofh56ic31vaccinationandadjunctivecyclooxygenase2inhibitortreatmentintuberculosispatients |
| _version_ |
1718407892893171712 |